Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Dr. Mace Rothenberg, MD

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Oct 21, 2021 1:02pm

153 Views

Post# 34033353

RE:RE:Dr. Mace Rothenberg, MD

"Dr. Rothenberg recently retired from Pfizer where he served as Chief Medical Officer from 2019 to 2021. During this time, the company initiated, completed, and obtained emergency use authorization for its COVID-19 vaccine. Prior to that role, Mace led Clinical Development for Oncology at Pfizer from 2008 to 2018. Over that 10 year period, his organization developed and obtained regulatory approval for 11 new cancer medicines."

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week